Brazil Starts Human Clinical Trials for U.K. COVID-19 Prototype Vaccine, an Industrial Info Market Brief

Brazil's National Health Regulatory Agency, ANVISA (Agencia Nacional de Vigilancia Sanitaria), has approved and started COVID-19 vaccine trials on 2,000 citizens in Sao Paulo. Brazil ranks second in the world for positive COVID-19 cases and related deaths, with Sao Paulo as the epicenter.

According to the Federal University of Sao Paulo, the clinical trials are vital for the authorization of a vaccine developed in the U.K., since the results are needed to move forward with the vaccine project by Oxford University and supported by AstraZeneca, which expects to commercialize it by the end of this year.

Industrial Info is tracking 16 COVID-19 related projects within the Latin America's Pharma-Bio sector worth $50.57 million, including six projects worth $31 million in Brazil.